VistaGen Therapeutics (NASDAQ:VTGN) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

VistaGen Therapeutics (NASDAQ:VTGN) announced its quarterly earnings data on Monday. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.03), FiscalAI reports. VistaGen Therapeutics had a negative net margin of 5,487.01% and a negative return on equity of 120.13%. The company had revenue of $0.38 million for the quarter, compared to analysts’ expectations of $0.40 million. During the same period in the prior year, the firm earned ($1.67) earnings per share.

VistaGen Therapeutics Trading Up 20.4%

NASDAQ VTGN opened at $0.69 on Wednesday. VistaGen Therapeutics has a 52 week low of $0.43 and a 52 week high of $5.14. The stock has a market cap of $27.34 million, a price-to-earnings ratio of -0.38 and a beta of 0.31. The company has a 50-day moving average price of $0.60 and a two-hundred day moving average price of $0.98.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on VTGN. Wall Street Zen downgraded shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, June 3rd. Four analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $0.95.

Institutional Trading of VistaGen Therapeutics

A number of institutional investors have recently made changes to their positions in VTGN. Bank of America Corp DE lifted its stake in shares of VistaGen Therapeutics by 1,068.0% in the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after acquiring an additional 19,331 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of VistaGen Therapeutics in the 1st quarter worth approximately $25,000. Marshall Wace LLP acquired a new stake in VistaGen Therapeutics during the second quarter valued at approximately $69,000. Jane Street Group LLC acquired a new stake in VistaGen Therapeutics during the second quarter valued at approximately $190,000. Finally, Dimensional Fund Advisors LP lifted its stake in VistaGen Therapeutics by 56.9% during the third quarter. Dimensional Fund Advisors LP now owns 68,017 shares of the company’s stock valued at $241,000 after purchasing an additional 24,655 shares during the last quarter. 78.39% of the stock is owned by institutional investors and hedge funds.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.